Semaglutide [amount hidden] Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE)

What Was Tested

This registered phase 4 trial tested Semaglutide.

In 2026, an international two-round modified Delphi study of 66 experts across surgery, obesity medicine, gastroenterology, endocrinology, dietetics, and psychology (Wills et al.) established consensus definitions.

It had two arms (groups): GLP 1 (active comparator) and Placebo (placebo comparator).

Matched placebo pen, identical escalation schedule, with the same lifestyle intervention.

The registry classes the interventions as drug.

More on the Plan

Randomized evidence for GLP-1 receptor agonism after MBS has accumulated rapidly but in populations that do not correspond to the new consensus definition of recurrent weight gain.

No randomized trial has enrolled patients selected by the consensus definition of recurrent weight gain.

Its participants were also a mean of 83.9 months, seven years, past surgery, long after recurrence had hardened.

In addition, one-anastomosis gastric bypass has appeared in a post-MBS randomized trial only as an unspecified fraction of BARI-STEP's 15-patient gastric-bypass subgroup; no trial has enrolled OAGB as a prespecified procedure stratum, and none has been conducted in a Middle East and North Africa population.

Who Took Part

Enrollment: 104 planned participants were the target.

It was open to people of any sex aged from 18 years up to 65 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Primary laparoscopic sleeve gastrectomy, Roux-en-Y gastric bypass, or one-anastomosis gastric bypass performed at least 18 months before screening. Current BMI \>=30 kg/m2, or \>=27 kg/m2 with at least one obesity-related complication (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, metabolic dysfunction-associated steatotic liver disease, or symptomatic osteoarthritis). Able and willing to self-inject weekly, complete the injection diary, attend scheduled visits, and provide written informed consent.

The full record lists 6 inclusion and 16 exclusion criteria; among the exclusions: revisional or conversion bariatric surgery of any type, or revisional surgery planned during the trial period; use of any glp-1-based therapy, tirzepatide, or other anti-obesity medication within 6 months of screening; type 1 diabetes; type 2 diabetes treated with insulin.

How the Study Was Run

The set-up was randomized, parallel-group and triple-blind.

Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.

The Semaglutide group and the comparison group ran side by side rather than switching.

As a double-blind Semaglutide study, the assignments were hidden from both participants and investigators until the end.

Those kept unaware of assignments: participant, investigator and outcomes assessor.

It started in 2026-10 with completion listed for 2029-04.

It ran at 1 site in Egypt.

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Mean percentage change in body weight from randomization (time frame: week 0 to week 68).

It also tracked 9 secondary outcomes, for example absolute weight change, BMI change, waist circumference change, change in HbA1c, systolic and diastolic blood pressure and total cholesterol, LDL, HDL, and triglycerides.

What This Means in Plain Language

Put simply, this is a phase 4, randomized trial of Semaglutide in 104 people.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.